×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JNJ – johnson & johnson (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JNJ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
08:08 am
jnj
Johnson & Johnson (NYSE:JNJ) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Johnson & Johnson (NYSE:JNJ) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/5
08:05 am
jnj
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi [Yahoo! Finance]
Low
Report
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi [Yahoo! Finance]
12/4
09:44 pm
jnj
Johnson & Johnson (JNJ): A Bull Case Theory [Yahoo! Finance]
Low
Report
Johnson & Johnson (JNJ): A Bull Case Theory [Yahoo! Finance]
12/4
07:03 pm
jnj
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
Low
Report
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
12/3
11:22 am
jnj
Intraocular Lens Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue [Yahoo! Finance]
Low
Report
Intraocular Lens Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue [Yahoo! Finance]
12/3
08:00 am
jnj
Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
Low
Report
Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
12/2
11:06 am
jnj
Medication Adherence Research Report 2025: Market to Reach $3.63 Billion by 2030, Driven by Rising Chronic Disease Burden, Aging Populations, and Growing Adoption of Digital Health Tools [Yahoo! Finance]
Low
Report
Medication Adherence Research Report 2025: Market to Reach $3.63 Billion by 2030, Driven by Rising Chronic Disease Burden, Aging Populations, and Growing Adoption of Digital Health Tools [Yahoo! Finance]
12/2
07:08 am
jnj
Johnson & Johnson (NYSE:JNJ) was given a new $197.00 price target on by analysts at Barclays PLC.
Low
Report
Johnson & Johnson (NYSE:JNJ) was given a new $197.00 price target on by analysts at Barclays PLC.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/1
04:16 pm
jnj
Form 4 JOHNSON & JOHNSON For: Nov 26 Filed by: MORIKIS JOHN G
Low
Report
Form 4 JOHNSON & JOHNSON For: Nov 26 Filed by: MORIKIS JOHN G
11/13
03:26 pm
jnj
Form 13F-HR JOHNSON & JOHNSON For: Sep 30
Neutral
Report
Form 13F-HR JOHNSON & JOHNSON For: Sep 30
10/22
04:04 pm
jnj
Form 10-Q JOHNSON & JOHNSON For: Sep 28
Low
Report
Form 10-Q JOHNSON & JOHNSON For: Sep 28
10/20
07:14 pm
jnj
Form 4 JOHNSON & JOHNSON For: Oct 17 Filed by: REED JOHN C
Low
Report
Form 4 JOHNSON & JOHNSON For: Oct 17 Filed by: REED JOHN C
10/17
10:24 am
jnj
Form 144 JOHNSON & JOHNSON Filed by: REED JOHN C
Low
Report
Form 144 JOHNSON & JOHNSON Filed by: REED JOHN C
10/14
07:23 am
jnj
Form 8-K JOHNSON & JOHNSON For: Oct 14
Low
Report
Form 8-K JOHNSON & JOHNSON For: Oct 14
9/15
04:37 pm
jnj
Form 3 JOHNSON & JOHNSON For: Sep 08 Filed by: MORIKIS JOHN G
Low
Report
Form 3 JOHNSON & JOHNSON For: Sep 08 Filed by: MORIKIS JOHN G
9/11
05:52 pm
jnj
Form 4 JOHNSON & JOHNSON For: Sep 09 Filed by: HEWSON MARILLYN A
Low
Report
Form 4 JOHNSON & JOHNSON For: Sep 09 Filed by: HEWSON MARILLYN A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/27
Form DEFA14A JOHNSON & JOHNSON
8.1%
3/12 Paul Harris' Top Picks: March 12, 2020 [Business News Network (BNN) Energy & Resources (Canada)] 7.5%
4/7 Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily] 4.6%
4/5 Will These 3 Coronavirus Stocks Lead the Market to Recovery? [Yahoo! Finance News] 4.3%
4/13 Stocks slip as market enters new phase, with investors worrying about balance sheets [CNBC] 4.0%
3/2 AODocs Joins AIIM Leadership Council, Showcases Innovative Approach to Information Management at 2020 AIIM Conference 3.9%
3/4 Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action [Reuters] 3.8%
3/18 Is This 1 Healthcare Stock Coronavirus-Proof? [The Motley Fool] 3.8%
3/24 What Technology And Manufacturing Can Do To Help Against COVID-19 [Forbes] 3.6%
4/1 5 of the Best Stocks to Buy for April [Yahoo! Finance News] 3.3%
3/12 Paul Harris' Top Picks: March 12, 2020 [Business News Network (BNN) Energy & Resources (Canada)] 7.5%
4/7 Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily] 4.6%
4/5 Will These 3 Coronavirus Stocks Lead the Market to Recovery? [Yahoo! Finance News] 4.3%
4/13 Stocks slip as market enters new phase, with investors worrying about balance sheets [CNBC] 4.0%
3/2 AODocs Joins AIIM Leadership Council, Showcases Innovative Approach to Information Management at 2020 AIIM Conference 3.9%
3/4 Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action [Reuters] 3.8%
3/18 Is This 1 Healthcare Stock Coronavirus-Proof? [The Motley Fool] 3.8%
3/24 What Technology And Manufacturing Can Do To Help Against COVID-19 [Forbes] 3.6%
4/1 5 of the Best Stocks to Buy for April [Yahoo! Finance News] 3.3%
TOP News Decliners
3/21
Johnson and Johnson: A Safe Haven in Recession [The Motley Fool]
-7.3%
3/20 Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? [Yahoo! Finance News] -6.9%
3/10 J&J MET antibody nabs accelerated review status for certain lung cancer patients [Seeking Alpha] -6.8%
3/18 J&J files U.S. application for MS med ponesimod [Seeking Alpha] -6.6%
10/18 Wolves In Sheep’s Clothing: We Can’t Trust Businesses To Do Right By Americans Now [Forbes] -6.4%
5/28 Oklahoma taking on Johnson & Johnson in historic trial [MSNBC.com] -6.1%
3/13 Americans rush to stock up on essentials as coronavirus spreads [Reuters] -5.5%
3/11 Desperate to exit, a $10B price tag for Magic Leap is crazy [TechCrunch Blog] -4.9%
7/12 Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating and a $156.00 price target on the stock. -4.5%
3/6 Eyecare industry leaders sign Proclamation to focus on key issues facing the future of optometry -3.8%
3/20 Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? [Yahoo! Finance News] -6.9%
3/10 J&J MET antibody nabs accelerated review status for certain lung cancer patients [Seeking Alpha] -6.8%
3/18 J&J files U.S. application for MS med ponesimod [Seeking Alpha] -6.6%
10/18 Wolves In Sheep’s Clothing: We Can’t Trust Businesses To Do Right By Americans Now [Forbes] -6.4%
5/28 Oklahoma taking on Johnson & Johnson in historic trial [MSNBC.com] -6.1%
3/13 Americans rush to stock up on essentials as coronavirus spreads [Reuters] -5.5%
3/11 Desperate to exit, a $10B price tag for Magic Leap is crazy [TechCrunch Blog] -4.9%
7/12 Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating and a $156.00 price target on the stock. -4.5%
3/6 Eyecare industry leaders sign Proclamation to focus on key issues facing the future of optometry -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: